glutathione sepharose 4b 10 µl of Sepharose™ beads were coated with GST or the such as native glutathione S Glutathione Sepharose 4B: GE Healthcare

Preclinical Research Summary Preclinical research references discuss BPC-157 and TB-500related observations derived from controlled experimental systems used to examine synthetic peptide materials within non-clinical research frameworks

Compounded drugs are not FDA-approved and are not evaluated for safety or efficacy by the FDA

This can involve dietary modification and improving understanding of nutrition

lowest tolerated dose Phase Step 2 Weeks Weeks 5-8 Cagrilintide Dose 0.5 mg/week Purpose Dose escalation Phase Step 3 Weeks Weeks 9-12 Cagrilintide Dose 1.0 mg/week Purpose GI side effects often peak here Phase Step 4 Weeks Weeks 13-16 Cagrilintide Dose 1.7 mg/week Purpose Approaching maintenance Phase Maintenance Weeks Weeks 17+ Cagrilintide Dose 2.4 mg/week Purpose Target dose used in late-stage study protocols Each step lasts 4 weeks

Capsules are plant-based